SILVERDALE, Wash., June 7, 2011 /PRNewswire/ -- Infrared Systems International (OTCBB: IFRS) is pleased to announce that its subsidiary, AquaLiv, Inc., has concluded a pilot study of its NatuRx™ HIV/AIDS treatment and will push forward with clinical trials in Kenya later this year.
AquaLiv concluded a pilot study with two HIV/AIDS patients this week which also happens to mark the 30th anniversary of the first reported AIDS victims on June 5th, 1981.
"The results of our pilot study indicate significant advances in the fight against HIV and AIDS," stated AquaLiv CEO Craig Hoffman. "AquaLiv's solution shows remarkable results and can do so at a much lower cost than traditional drugs currently on the market. For developing nations this could really be a game changer."
In August, Mr. Emmanuel Mutisya, a Kenyan with United Nations University, will accompany AquaLiv representatives to Kenya and aid in the identification of clinics capable of carrying out the clinical trials. "Earlier this year, Mr. Mutisya supplied 10 Kenyans with our NatuRx™ HIV/AIDS treatment. Since then, they stopped taking their costly antiretroviral drugs and their condition has improved. Mr. Mutisya is now a believer in AquaLiv technology," added Mr. Hoffman.
One study participant infected with Hepatitis C in addition to HIV observed significantly reduced Hepatitis C viral loads as an additional benefit of the treatment. Mr. Hoffman continued, "We are working on several NatuRx™ treatments for a variety of diseases. The technology has proven effective with all the bacterial and viral conditions we've tested. If given the opportunity, we are confident we could quickly have a positive impact on those infected with the new strain of deadly E.coli bacteria."
Based on AquaLiv's patented BioT™ Bioinformation Technology, NatuRx™ formulations utilize novel wave-based information composites in lieu of molecules for treatment. The solutions hav
|SOURCE Infrared Systems International|
Copyright©2010 PR Newswire.
All rights reserved